Onconova Therapeutics, Pangea Biomed Collaborate on AI-Driven Cancer Biomarker Study
The companies will apply Pangea's ENLIGHT platform to map gene interactions in pathways modulated by Onconova's investigational cancer therapy rigosertib.
The most recent software, Paraphase, produces "mini haplotypes" rather than counting copy number variations to identify variants linked to rare diseases.
By mapping individual cells to a scRNA-seq atlas, the new computational method seeks to fill in missing pieces in transcriptomes and advance cancer drug discovery.
The new method from a KU Leuven team offers insights into clonal profiling with applications in minimal residual disease.
By participating in Accenture's Project Spotlight, the transcriptomics-focused bioinformatics startup seeks to form biomarker discovery partnerships with top 25 pharma firms.